Alliances
Partnering with Hong Kong-based Sinovant Sciences, which is one of Ramaswamy’s “vant” companies, Roivant and Sinovant are launching a company called Cytovant Sciences.
ViiV Healthcare, presented three-year data from the SWORD 1 and 2 clinical trials in HIV. The data was presented at the 25th Annual Conference of the British HIV Association (BHIVA) in Bournemouth, UK.
Cambridge, Mass.-based Editas Medicine and privately-held BlueRock Therapeutics have teamed up and combined their genome editing and cell therapy technologies to discover, develop and manufacture novel engineered cell medicines.
The California-based company also shared positive early data from a beta thalassemia study and announced plans to increase AAV manufacturing.
The Lead Discovery Center and the Korean Drug Development Fund have entered into an agreement to facilitate the interaction between LDC and the prospering South Korean biotech scene.
Gilead Sciences and Belgium-based Galapagos NV reported positive late-stage results from its FINCH 1 and FINCH 3 rheumatoid arthritis studies.
AstraZeneca signed a global development and commercialization deal with Daiichi Sankyo Company for trastuzumab deruxtecan (DS-8201).
South San Francisco-based Mission Bio, the only company providing single-cell DNA sequencing, entered into a collaboration with LabCorp, to harness the abilities of the company’s Tapestri Platform to provide more precise clinical trials.
BMS inked a multi-year strategic agreement with Concerto HealthAI, which focuses on oncology-specific Real-World Data (RWD) and advanced AI for Real-World Evidence (RWE) generation.
The rumors speculated that AstraZeneca planned to acquire Aveo in the second quarter of this year in order to gain the company’s kidney cancer drug, Tivozanib.
PRESS RELEASES